LIPS-A: Lung Injury Prevention Study With Aspirin

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Acute Respiratory Distress Syndrome
Interventions
DRUG

Aspirin

325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.

DRUG

Lactose powder

Matching lactose powder filled capsules will be administered on days 1-7.

Trial Locations (16)

10467

Montefiore Medical Center, The Bronx

19140

Temple University School of Medicine, Philadelphia

27517

Wake Forest University Medical Center, Winston-Salem

27710

Duke University Medical Center, Durham

32224

Mayo Clinic in Florida, Jacksonville

32610

University of Florida, Gainsville

40202

University of Louisville Medical Center, Louisville

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic in Rochester, Rochester

60612

University of Illinois at Chicago, Chicago

94305

Stanford Univeristy, Stanford

98104

Harborview Medical Center, Seattle

06610

Bridgeport Hospital, Bridgeport

021114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Montefiore Medical Center

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER

NCT01504867 - LIPS-A: Lung Injury Prevention Study With Aspirin | Biotech Hunter | Biotech Hunter